imatinib mesylate has been researched along with Chylothorax in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, J; Huang, J; Jiang, Q; Lin, H; Wu, L; Ye, Q | 1 |
| Jing, Y; Lu, N; Yang, L; Yu, L | 1 |
2 other study(ies) available for imatinib mesylate and Chylothorax
| Article | Year |
|---|---|
Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
Topics: Adverse Drug Reaction Reporting Systems; Chylothorax; Dasatinib; Female; Humans; Imatinib Mesylate; Pericardial Effusion; Pharmacovigilance; Pleural Effusion; Pulmonary Edema; Pyrimidines; Retrospective Studies; United States; United States Food and Drug Administration | 2023 |
[Chylothorax Related with Dasatinib in the Treatment of Chronic Myeloid Leukemia: Report of 3 Cases].
Topics: Chylothorax; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pleural Effusion; Prognosis; Protein Kinase Inhibitors | 2016 |